SUMMIT THERAPEUTICS INC.

Transcripts Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Market Closed - Nasdaq Other stock markets 21:00:00 09/05/2024 BST			5-day change	1st Jan Change
4.78 ^USD	-3.63%		+17.73%	+83.14%

05-07	Citigroup Starts Summit Therapeutics With Buy Rating, $7 Price Target	MT
05-01	Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024

Transcripts

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Transcript : Summit Therapeutics Inc., Q1 2024 Earnings Call, May 01, 2024	05-01
Transcript : Summit Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02:35 PM	03-12
Transcript : Summit Therapeutics Inc., Q4 2023 Earnings Call, Feb 20, 2024	02-20
Transcript : Summit Therapeutics Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 01:30 PM	01-09
Transcript : Summit Therapeutics Inc., Q3 2023 Earnings Call, Nov 07, 2023	11-07
Transcript : Summit Therapeutics Inc., Q2 2023 Earnings Call, Aug 09, 2023	09/08/23
Transcript : Summit Therapeutics Inc., Q1 2023 Earnings Call, May 11, 2023	11/05/23
Transcript : Summit Therapeutics Inc., Q4 2022 Earnings Call, Mar 09, 2023	09/03/23
Transcript : Summit Therapeutics Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 03:45 PM	09/01/23
Transcript : Summit Therapeutics Inc. Presents at JPMorgan 40th Annual Healthcare Conference, Jan-10-2022 03:45 PM	10/01/22
Transcript : Summit Therapeutics plc - Shareholder/Analyst Call	24/06/20
Transcript : Summit Therapeutics plc, Q2 2020 Earnings Call, Oct 11, 2019	11/10/19
Transcript : Summit Therapeutics plc - Special Call	07/10/19
Transcript : Summit Therapeutics plc, Q4 2019 Earnings Call, Mar 27, 2019	27/03/19
Transcript : Summit Therapeutics plc, Q2 2019 Earnings Call, Sep 20, 2018	20/09/18

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer